Bora Pharmaceuticals, a Taiwan-based international contract development and manufacturing organization, will locate its first North American manufacturing facility and corporate headquarters in Mississauga, Ontario, Canada.
Establishing the Mississauga site as part of its global manufacturing network is key to Bora Pharmaceuticals' growth strategy. From its new facility, Bora Pharmaceuticals is now positioned to produce 50 different products for 100 markets worldwide.
"This expansion into North America brings us closer to many of our customers and adds the capabilities to welcome new ones onboard," said Bobby Sheng, CEO of Bora Pharmaceuticals. "The Mississauga site strengthens our existing state-of-the-art manufacturing network, whilst adding a number of talented colleagues that will help us develop further in the region."
Through its acquisition of GSK's Mississauga facility, which is now complete, the company has taken a major step forward with its expansion into North America. Bora Pharmaceuticals will employ approximately 400 skilled manufacturing employees from their Mississauga site and plans to recruit additional employees to further strengthen its technical and operations team.
"We are so pleased that Bora Pharmaceuticals' North American operations will be headquartered in Mississauga," said Bonnie Brown, Director of Economic Development. "With more than 470 businesses and over 25,000 employees already working in our thriving life sciences sector, including key contract development and manufacturing organizations, we remain steadfast in our commitment to creating a sustainable environment that supports bringing medical innovation to market in Mississauga that will benefit the world."